Anti-FOLR1/ FBP/ FOLR monoclonal antibody
Anti-FOLR1/ FBP/ FOLR antibody for FACS & in-vivo assay
Go to FOLR1/FOLR1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T83386-Ab-1/ GM-Tg-hg-T83386-Ab-2 | Anti-Human FOLR1 monoclonal antibody | Human |
GM-Tg-rg-T83386-Ab-1/ GM-Tg-rg-T83386-Ab-2 | Anti-Rat FOLR1 monoclonal antibody | Rat |
GM-Tg-mg-T83386-Ab-1/ GM-Tg-mg-T83386-Ab-2 | Anti-Mouse FOLR1 monoclonal antibody | Mouse |
GM-Tg-cynog-T83386-Ab-1/ GM-Tg-cynog-T83386-Ab-2 | Anti-Cynomolgus/ Rhesus macaque FOLR1 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T83386-Ab-1/ GM-Tg-felg-T83386-Ab-2 | Anti-Feline FOLR1 monoclonal antibody | Feline |
GM-Tg-cang-T83386-Ab-1/ GM-Tg-cang-T83386-Ab-2 | Anti-Canine FOLR1 monoclonal antibody | Canine |
GM-Tg-bovg-T83386-Ab-1/ GM-Tg-bovg-T83386-Ab-2 | Anti-Bovine FOLR1 monoclonal antibody | Bovine |
GM-Tg-equg-T83386-Ab-1/ GM-Tg-equg-T83386-Ab-2 | Anti-Equine FOLR1 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T83386-Ab-1/ GM-Tg-hg-T83386-Ab-2; GM-Tg-rg-T83386-Ab-1/ GM-Tg-rg-T83386-Ab-2; GM-Tg-mg-T83386-Ab-1/ GM-Tg-mg-T83386-Ab-2; GM-Tg-cynog-T83386-Ab-1/ GM-Tg-cynog-T83386-Ab-2; GM-Tg-felg-T83386-Ab-1/ GM-Tg-felg-T83386-Ab-2; GM-Tg-cang-T83386-Ab-1/ GM-Tg-cang-T83386-Ab-2; GM-Tg-bovg-T83386-Ab-1/ GM-Tg-bovg-T83386-Ab-2; GM-Tg-equg-T83386-Ab-1/ GM-Tg-equg-T83386-Ab-2 |
Products Name | Anti-FOLR1 monoclonal antibody |
Format | mab |
Target Name | FOLR1 |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-FOLR1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Biosimilar | GMP-Bios-INN-850 | Pre-Made Farletuzumab Ecteribulin Biosimilar, Whole Mab Adc, Anti-Folr1 Antibody: Anti-FBP/FOLR/FRalpha/NCFTD therapeutic antibody Drug Conjugate |
Biosimilar | GMP-Bios-ab-349 | Pre-Made Mirvetuximab biosimilar, Whole mAb ADC, Anti-FOLR1 Antibody: Anti-FBP/FOLR/FRalpha/NCFTD therapeutic antibody |
Biosimilar | GMP-Bios-INN-914 | Pre-Made Mirvetuximab Soravtansine Biosimilar, Whole Mab Adc, Anti-Folr1 Antibody: Anti-FBP/FOLR/FRalpha/NCFTD therapeutic antibody Drug Conjugate |
Biosimilar | GMP-Bios-ab-205 | Pre-Made Farletuzumab biosimilar, Whole mAb, Anti-FOLR1 Antibody: Anti-FBP/FOLR/FRalpha/NCFTD therapeutic antibody |
Target Antigen | Products Developing | Multi-species FOLR1/ FBP/ FOLR VLP (virus-like particle) (Products Developing) |
ORF Viral Vector | pGMLP000860 | human FOLR1 Lentivirus plasmid |
ORF Viral Vector | vGMLP000860 | human FOLR1 Lentivirus particle |
ORF Viral Vector | pGMLPm000941 | mouse Folr1 Lentivirus plasmid |
ORF Viral Vector | vGMLPm000941 | mouse Folr1 Lentivirus particle |
Target information
Target ID | GM-T83386 |
Target Name | FOLR1 |
Gene ID | 2348,14275,171049,718388,101084221,539750,100066084 |
Gene Symbol and Synonyms | FBP,FBP1,Folbp-1,Folbp1,FOLR,FOLR1,FRalpha,NCFTD |
Uniprot Accession | P15328 |
Uniprot Entry Name | FOLR1_HUMAN |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target, Immuno-oncology Target, INN Index |
Disease | Ovary Cancer |
Gene Ensembl | ENSG00000110195 |
Target Classification | Checkpoint-Immuno Oncology |
The target: FOLR1, gene name: FOLR1, also named as FBP, FOLR. The protein encoded by this gene is a member of the folate receptor family. Members of this gene family bind folic acid and its reduced derivatives, and transport 5-methyltetrahydrofolate into cells. This gene product is a secreted protein that either anchors to membranes via a glycosyl-phosphatidylinositol linkage or exists in a soluble form. Mutations in this gene have been associated with neurodegeneration due to cerebral folate transport deficiency. Due to the presence of two promoters, multiple transcription start sites, and alternative splicing, multiple transcript variants encoding the same protein have been found for this gene. [provided by RefSeq, Oct 2009].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.